Progesterone: Evidence-Based Review

Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

**Progesterone**, a vital endogenous steroid hormone, holds a central and multifaceted role in human physiology, particularly within the female reproductive ...

Progesterone, a vital endogenous steroid hormone, holds a central and multifaceted role in human physiology, particularly within the female reproductive system. Its influence extends from the intricate regulation of the menstrual cycle and the establishment of pregnancy to the maintenance of a healthy gestation. Beyond its reproductive functions, progesterone contributes significantly to bone health, neurological well-being, and cardiovascular function. The therapeutic application of progesterone, both bioidentical and synthetic (progestins), is widespread, addressing conditions such as infertility, recurrent miscarriage, preterm birth, and menopausal symptoms. A comprehensive understanding of the evidence base supporting these applications is crucial for healthcare professionals and patients seeking to leverage its therapeutic potential. This review aims to synthesize the robust body of clinical evidence, highlighting key studies, efficacy data, and safety considerations that define progesterone's role in modern medical practice, ensuring informed decision-making and optimized patient outcomes.

What Is Progesterone?

Progesterone is a naturally occurring steroid hormone, primarily synthesized from cholesterol by the corpus luteum in the ovaries after ovulation and by the placenta during pregnancy. It is the principal hormone of the progestogen class. In clinical settings, bioidentical progesterone refers to formulations that are chemically identical to the hormone produced by the human body, often micronized for improved oral absorption. It is distinct from progestins, which are synthetic compounds designed to mimic some of progesterone's actions but may have different pharmacological properties and side effect profiles. Progesterone's primary physiological role is to prepare the endometrium for embryo implantation and to maintain pregnancy. Its broader actions include neuroprotective effects, modulation of mood, and contributions to bone mineral density.

How It Works

Progesterone exerts its diverse physiological effects by binding to specific intracellular progesterone receptors (PRs), which are members of the steroid hormone receptor superfamily. These receptors are widely distributed throughout the body, including the uterus, ovaries, breasts, brain, and bone. Upon binding, the progesterone-receptor complex undergoes a conformational change, translocates to the nucleus, and binds to specific DNA sequences known as progesterone response elements (PREs). This interaction modulates gene transcription, leading to the synthesis of specific proteins that mediate progesterone's biological actions.

In the female reproductive system, progesterone's primary actions include:

Endometrial Preparation: After ovulation, progesterone transforms the estrogen-primed proliferative endometrium into a secretory endometrium, making it receptive to embryo implantation. It promotes glandular secretion, stromal decidualization, and reduces uterine contractility.

Pregnancy Maintenance: During pregnancy, high levels of progesterone, initially from the corpus luteum and later from the placenta, are crucial. Progesterone maintains uterine quiescence by inhibiting myometrial contractions, prevents immunological rejection of the fetus, and supports the growth and development of the embryo and fetus.

Menstrual Cycle Regulation: Progesterone's cyclical rise and fall regulate the timing of menstruation. A drop in progesterone levels at the end of the luteal phase triggers the shedding of the endometrial lining.

Prevention of Preterm Birth: Numerous randomized controlled trials and meta-analyses have established the efficacy of progesterone supplementation in reducing the risk of preterm birth. A landmark Cochrane review by Dodd et al. (2013) synthesized data from multiple trials, concluding that progesterone administration (vaginal or intramuscular) significantly reduced the risk of preterm birth and neonatal morbidity in women at high risk Dodd et al., 2013. Subsequent guidelines from organizations like ACOG have incorporated these findings, recommending progesterone for women with a history of spontaneous preterm birth or a short cervix ACOG, 2023.

Recurrent Miscarriage: The role of progesterone in preventing recurrent miscarriages has been a subject of ongoing research. While earlier studies yielded mixed results, more recent large-scale trials, such as the PRISM trial, have provided clearer insights. The PRISM trial, while not showing a benefit for all women with early pregnancy bleeding, did suggest a potential benefit in subgroups, particularly those with a history of recurrent miscarriage Coomarasamy et al., 2019. Further research continues to refine the specific indications for progesterone in this context.

Assisted Reproductive Technology (ART): Progesterone is a standard component of luteal phase support in ART cycles, including in vitro fertilization (IVF). Its use is critical for optimizing endometrial receptivity and improving pregnancy rates. Evidence consistently demonstrates that adequate progesterone levels during the luteal phase are essential for successful implantation and early pregnancy maintenance in ART Devine et al., 2017.

Menopausal Hormone Therapy (MHT):

Endometrial Protection: For postmenopausal women with an intact uterus receiving estrogen therapy to manage menopausal symptoms, progesterone is unequivocally indicated to protect the endometrium. Clinical evidence, notably from the Women's Health Initiative (WHI) study, demonstrated that unopposed estrogen therapy significantly increased the risk of endometrial hyperplasia and cancer, a risk mitigated by the addition of progesterone Writing Group for the Women's Health Initiative Investigators, 2002.

Symptom Management: Beyond endometrial protection, progesterone can also contribute to the alleviation of menopausal symptoms, including hot flashes and sleep disturbances, and may have positive effects on mood and cognitive function Prior, 2018.

Bone Health:

Preclinical and clinical studies indicate that progesterone, often in synergy with estrogen, plays a crucial role in maintaining bone mineral density. It stimulates osteoblast activity (bone formation) and inhibits osteoclast activity (bone resorption), thereby contributing to bone formation and protection against osteoporosis Cable et al., 2023.

Vaginal Progesterone: Commonly prescribed as 100-200 mg two to three times daily (e.g., suppositories, gels, or inserts). Administration typically begins after oocyte retrieval and continues until 8-12 weeks of gestation, or as directed by the fertility specialist.

Oral Micronized Progesterone: Doses typically range from 200-400 mg once daily, usually taken at bedtime. This route is also initiated after oocyte retrieval and continued through early pregnancy.

Intramuscular Progesterone: 50-100 mg daily of progesterone in oil. This route is less common due to patient discomfort but may be used in specific cases.

For Prevention of Preterm Birth:

Vaginal Progesterone: 200 mg daily (suppository or gel) is typically administered from approximately 16-20 weeks of gestation until 34-36 weeks of gestation. This is recommended for women with a history of spontaneous preterm birth or a short cervix.

17-alpha Hydroxyprogesterone Caproate (17P) Injection: 250 mg intramuscularly once weekly from 16-20 weeks until 36 weeks of gestation. This is specifically for women with a history of spontaneous preterm birth.

For Menopausal Hormone Therapy (with Estrogen):

Oral Micronized Progesterone:

Cyclic Regimen: 200 mg daily for 12-14 consecutive days per 28-day cycle. This regimen is designed to induce a monthly withdrawal bleed, mimicking a natural menstrual cycle.

Continuous Combined Regimen: 100 mg daily continuously. This aims to achieve amenorrhea (no bleeding) in most women, providing continuous endometrial protection.

Transdermal Progesterone: Dosing varies by product and is typically applied daily as a cream or gel.

For Menstrual Irregularities/Endometriosis:

Table 1: Progesterone Dosing and Protocol Summary

| Indication | Formulation & Dose | Frequency | Duration | Administration Notes |

| :--------------------------------------------- | :----------------------------------------------- | :---------------- | :--------------------------------------------- | :-------------------------------------------------- |

| Luteal Phase Support (ART) | Vaginal: 100-200 mg | 2-3 times daily | Until 8-12 weeks gestation | Suppositories, gels, or inserts |

| | Oral Micronized: 200-400 mg | Once daily | Until 8-12 weeks gestation | At bedtime |

| | IM: 50-100 mg | Once daily | Until 8-12 weeks gestation | Progesterone in oil |

| Prevention of Preterm Birth | Vaginal: 200 mg | Once daily | 16-20 weeks to 34-36 weeks gestation | Suppository or gel |

| | 17P Injection: 250 mg | Once weekly | 16-20 weeks to 36 weeks gestation | Intramuscular |

| Menopausal Hormone Therapy (with Estrogen) | | | | |

| Cyclic Regimen | Oral Micronized: 200 mg | Daily for 12-14 days | Per 28-